ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting |
- Home
- Clinician Education
- COVID-19 Remdesivir Toolkit
SIDP has developed guidance documents pertaining to the use of remdesivir (Veklury®) for the treatment of COVID-19 for both outpatient and inpatient administration of 3 and 5 day regimens, informed by the experiences of pharmacists who have implemented remdesivir therapeutic regimens at their medical centers. Toolkit Features:
|
|
SIDP member, Drew Zimmer, PharmD (left), discussing therapeutic options for COVID-19 with a colleague.
How to use this Toolkit
1. Review toolkit contents. 2. Download documents and customize (if needed) to fit your institutional needs. 3. Review educational materials and customize (if needed) to fit your institutional needs. |
Toolkit Contents
- Criteria for use
- Some centers might consider developing locally validated scoring tools or risk stratification systems to help with identifying patients that will benefit the most from remdesivir for COVID-19 if issues with limited supply or for more targeted use based on availability of resources.
- Examples of available scoring tools and risk stratification criteria to aid in prioritization:
- In developing scoring tools/risk stratification systems for prioritizing 3-day courses of remdesivir, it may be important to note the most common comorbidities among those included in the PINETREE Trial (diabetes, obesity, and hypertension) and that the mean age for patients included was 50 years. A higher ‘weighting’ or score for those 50 and older with these comorbidities may be considered.
- Provider Education
- Provider Education – Remdesivir Overview
- Provider quick reference guide
- Talking points for providers regarding remdesivir
- Nursing Education
- Patient Education
- Billing, reimbursement information, coding
- Assistance for access to remdesivir is available through the Gilead Advancing Access to identify locations offering outpatient remdesivir therapy program
- Offers assistance with co-pay information, coding/reimbursement, verification
- Contact: 1-800-226-2056 (option 4); M-F 0900-2000 EST
- Remdesivir is FDA approved and available commercially
- Medical providers may refer to the US Government’s Administration for Strategic Preparedness & Response (ASPR) COVID-19 Therapeutics Locator tool to identify locations offering outpatient remdesivir therapy
Updates and revisions to toolkit contents will be made every 2 weeks, as needed, until May 2024.
Revisit this page periodically for the most up-to-date information!
Submit Toolkit Feedback and Suggestions | Subscribe to Hear About New Educational Offerings from SIDP |
Disclaimer
Please keep in mind that information, data regarding COVID-19 therapeutics is constantly evolving. Use of SIDP guidelines and/or toolkits are intended as recommendations. Use does not supersede clinical judgement based on the assessment of an individual patient by an individual practitioner. The recommendations reflect the best available evidence at the time of publication and are not the sole resource for patient care management and/or an exclusive source of action.
SIDP COVID-19 Remdesivir Toolkit Taskforce Members
Special thanks to the following SIDP members for volunteering their time and efforts to the development of this toolkit:
|  SIDP Member, Christina O'Connor, PharmD (left) discussing therapeutic options for COVID-19 with an advanced practice practitioner colleague.
|
This toolkit was supported in part by Gilead Sciences, Inc. All content creation and peer review were conducted independently by SIDP members.
Release Date 5/10/2023, Updated 8/11/2023
|
.gif){kind=logo}
Society of Infectious Diseases Pharmacists • PO Box 1488, Warrenville, IL 60555
(331) 248-7888 • sidp@affinity-strategies.com
Proudly Managed by Affinity Strategies